Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 21.8% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price shot up 21.8% during mid-day trading on Tuesday . The company traded as high as $0.49 and last traded at $0.50. 48,603,004 shares traded hands during trading, a decline of 43% from the average session volume of 85,729,586 shares. The stock had previously closed at $0.41.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average price of $0.28 and a two-hundred day moving average price of $0.28. The company has a market cap of $85.99 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.